Article
Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine - 1 Nov 2004
Barth Rolf F, Wu Gong, Yang Weilian, Binns Peter J, Riley Kent J, Patel Hemant, Coderre Jeffrey A, Tjarks Werner, Bandyopadhyaya A K, Thirumamagal B T S, Ciesielski Michael J, Fenstermaker Robert A
Abstract excerpt
Cetuximab (IMC-C225) is a monoclonal antibody directed against both the wild-type and mutant vIII isoform of the epidermal growth factor receptor (EGFR). The purpose of the present study was to evaluate the monoclonal antibody (MoAb), cetuximab, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors. Twenty-four hours following intratumoral (i.t.) administration of boronated cetuximab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.